RxDoctor Payments Data

Ryan Kahl, DO

Internal Medicine · Sherman, TXNPI 1275911109

Payments from drug & device makers

$6,947in general payments, 2019–2025

Across 240 payments — averaging $28.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Gilead$611
  • Regeneron Healthcare Solutions, Inc.$411
  • Takeda Pharmaceuticals U.S.A., Inc.$388
  • Johnson & Johnson$377
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$337
  • plus $2K from 30 others

What the payments were for

  • Food & beverage$6,84899%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,947 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$120,185
Medicare patients
357
Services billed
1,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$335,794
LinzessLinaclotide60$42,748
XifaxanRifaximin13$35,625
Mesalamine42$12,043
ClenpiqSod Picosulf/Mag Ox/Citric Ac66$10,753
Omeprazole227$3,263
Famotidine189$2,592
Colestipol Hcl47$2,262
Rabeprazole Sodium51$2,127
Pantoprazole Sodium134$1,658
Mesalamine ErMesalamine11$1,638
Esomeprazole Magnesium50$1,585
Budesonide EcBudesonide12$1,264
Budesonide DrBudesonide12$697
CholestyramineCholestyramine (With Sugar)14$689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$377$335,79412 claims
AbbVieLinzess$2,372$42,74860 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$337$35,62513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Sherman

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →